WO2000021516A3 - Methods for inhibiting diabetic complications - Google Patents

Methods for inhibiting diabetic complications Download PDF

Info

Publication number
WO2000021516A3
WO2000021516A3 PCT/US1999/023869 US9923869W WO0021516A3 WO 2000021516 A3 WO2000021516 A3 WO 2000021516A3 US 9923869 W US9923869 W US 9923869W WO 0021516 A3 WO0021516 A3 WO 0021516A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
diabetic complications
treat
instant invention
post
Prior art date
Application number
PCT/US1999/023869
Other languages
French (fr)
Other versions
WO2000021516A2 (en
Inventor
Billy G Hudson
Raja Gabriel Khalifah
Original Assignee
Billy G Hudson
Kansas University Medical Ct R
Raja Gabriel Khalifah
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US10427698P priority Critical
Priority to US60/104,276 priority
Application filed by Billy G Hudson, Kansas University Medical Ct R, Raja Gabriel Khalifah filed Critical Billy G Hudson
Publication of WO2000021516A2 publication Critical patent/WO2000021516A2/en
Publication of WO2000021516A3 publication Critical patent/WO2000021516A3/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415Pyridoxine, i.e. Vitamin B6

Abstract

The instant invention provides compositions and methods for modeling post-Amadori AGE formation and the identification and characterization of effective inhibitors of post-amadori AGE formation, and such identified inhibitor compositions. The instant invention also teaches new methods to treat or prevent diabetic nephropathy, oxidative stress, and protein crosslinking, comprising administering an amount effective of one of the compounds of the invention to treat or prevent the disorder.
PCT/US1999/023869 1998-10-14 1999-10-13 Methods for inhibiting diabetic complications WO2000021516A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10427698P true 1998-10-14 1998-10-14
US60/104,276 1998-10-14

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AU11125/00A AU1112500A (en) 1998-10-14 1999-10-13 Methods for inhibiting diabetic complications

Publications (2)

Publication Number Publication Date
WO2000021516A2 WO2000021516A2 (en) 2000-04-20
WO2000021516A3 true WO2000021516A3 (en) 2001-01-04

Family

ID=22299580

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/023869 WO2000021516A2 (en) 1998-10-14 1999-10-13 Methods for inhibiting diabetic complications

Country Status (2)

Country Link
AU (1) AU1112500A (en)
WO (1) WO2000021516A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60121794D1 (en) * 2000-11-02 2006-09-07 Univ South Carolina Use of pyridoxamine for the treatment and suppression of complications related to adipositas
US6521645B2 (en) 2000-11-20 2003-02-18 The University Of Kansas Medical Center Methods for the treatment and prevention of urinary stone disease
US8822542B2 (en) 2004-10-20 2014-09-02 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
US20080032990A1 (en) * 2006-07-07 2008-02-07 Khalifah Raja G Inhibitors of advanced glycation end products
WO2011008202A1 (en) * 2009-07-15 2011-01-20 Vanderbilt University Isoketal scavengers and mitigation of disorders involving oxidative injury
WO2013012715A1 (en) * 2011-07-15 2013-01-24 Vanderbilt University Methods for treating inflammation
WO2018201074A1 (en) * 2017-04-27 2018-11-01 Vanderbilt University Methods for treating atherosclerosis with gamma-ketoaldehyde scavengers

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2349330A1 (en) * 1976-04-29 1977-11-25 Savini Emile Compsns. contg. pyridoxine and an antioxidant esp. tocopherol - used for treatment of hyperlipidaemia
DE3542309A1 (en) * 1985-11-29 1987-06-04 Cardona Federico Dr Medicinal antioxidant
WO1992002216A1 (en) * 1990-08-01 1992-02-20 Univ Rockefeller Advanced glycation inhibitors containing amino-benzoic acids and derivatives, and methods of use
EP0474874A1 (en) * 1990-02-19 1992-03-18 Senju Pharmaceutical Co., Ltd. Maillard Reaction inhibitor compositions
WO1994000135A1 (en) * 1992-06-30 1994-01-06 Shapiro Howard K Composition containing amine and amine-related derivatives of benzoic acid and uses therefor including treating inflammatory diseases
US5288716A (en) * 1987-02-18 1994-02-22 Ulrich Speck Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and atherosclerosis
WO1997009981A1 (en) * 1995-09-12 1997-03-20 University Of Kansas Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
JPH09221425A (en) * 1996-02-13 1997-08-26 Taiho Yakuhin Kogyo Kk Thiol protease inhibitor
JPH10158244A (en) * 1996-12-02 1998-06-16 Kissei Pharmaceut Co Ltd 5-aminoalkyl-4-aminomethyl-3-hydroxypyridine derivative and maillard reaction inhibitor containing the same
JPH10175954A (en) * 1996-12-12 1998-06-30 Kissei Pharmaceut Co Ltd 4-aminomethyl-3-hydroxypyridine derivative and maillard reaction inhibitor containing the same
WO1999025690A2 (en) * 1997-11-17 1999-05-27 University Of Kansas Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
WO2000022094A2 (en) * 1998-10-09 2000-04-20 Kansas University Medical Center Methods for inhibiting oxidative modification of proteins

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2349330A1 (en) * 1976-04-29 1977-11-25 Savini Emile Compsns. contg. pyridoxine and an antioxidant esp. tocopherol - used for treatment of hyperlipidaemia
DE3542309A1 (en) * 1985-11-29 1987-06-04 Cardona Federico Dr Medicinal antioxidant
US5288716A (en) * 1987-02-18 1994-02-22 Ulrich Speck Use of pyridoxine derivatives in the prevention and treatment of hyperlipidaemia and atherosclerosis
EP0474874A1 (en) * 1990-02-19 1992-03-18 Senju Pharmaceutical Co., Ltd. Maillard Reaction inhibitor compositions
WO1992002216A1 (en) * 1990-08-01 1992-02-20 Univ Rockefeller Advanced glycation inhibitors containing amino-benzoic acids and derivatives, and methods of use
WO1994000135A1 (en) * 1992-06-30 1994-01-06 Shapiro Howard K Composition containing amine and amine-related derivatives of benzoic acid and uses therefor including treating inflammatory diseases
WO1997009981A1 (en) * 1995-09-12 1997-03-20 University Of Kansas Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
JPH09221425A (en) * 1996-02-13 1997-08-26 Taiho Yakuhin Kogyo Kk Thiol protease inhibitor
JPH10158244A (en) * 1996-12-02 1998-06-16 Kissei Pharmaceut Co Ltd 5-aminoalkyl-4-aminomethyl-3-hydroxypyridine derivative and maillard reaction inhibitor containing the same
JPH10175954A (en) * 1996-12-12 1998-06-30 Kissei Pharmaceut Co Ltd 4-aminomethyl-3-hydroxypyridine derivative and maillard reaction inhibitor containing the same
WO1999025690A2 (en) * 1997-11-17 1999-05-27 University Of Kansas Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
WO2000022094A2 (en) * 1998-10-09 2000-04-20 Kansas University Medical Center Methods for inhibiting oxidative modification of proteins

Non-Patent Citations (11)

* Cited by examiner, † Cited by third party
Title
"THE MECK MANUAL", 1987, MERCK SHARP & DOHME RESEARCH LABORATORIES, RAHWAY, N.J., XP002135612 *
BAYNES, J. W. ET AL: "Pyridorin, a post-Amadori inhibitor of advanced glycation reactions, preserves renal function in diabetic rats.", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, (SEPT., 1998) VOL. 9, NO. PROGRAM AND ABSTR. ISSUE, PP. 628A. MEETING INFO.: 31ST ANNUAL MEETING OF THE AMERICAN SOCIETY OF NEPHROLOGY PHILADELPHIA, PENNSYLVANIA, USA OCTOBER 25-28, 1998 AMERICAN SOCIETY, XP000901645 *
BOOTH A A ET AL: "IN VITRO KINETIC STUDIES OF FORMATION OF ANTIGENIC ADVANCED GLYCATION END PRODUCTS (AGES)", JOURNAL OF BIOLOGICAL CHEMISTRY,US,AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, vol. 272, no. 9, 28 February 1997 (1997-02-28), pages 5430 - 5437, XP002068236, ISSN: 0021-9258 *
BOOTH A A ET AL: "THIAMINE PYROPHOSPHATE AND PYRIDOXAMINE INHIBIT THE FORMATION OF ANTIGENIC ADVANCED GLYCATION END-PRODUCTS: COMPARISON WITH AMINOGUANIDINE", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS,US,ACADEMIC PRESS INC. ORLANDO, FL, vol. 220, no. 1, 1 January 1996 (1996-01-01), pages 113 - 119, XP002024845, ISSN: 0006-291X *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; IYOBE, AKIRA ET AL: "4-aminomethyl-3-hydroxypyridines and Maillard reaction inhibitors containing them", XP002135574, retrieved from STN Database accession no. 129:131256 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; IYOBE, AKIRA ET AL: "5-Aminoalkyl-4-aminomethyl-3-hydroxypyridines and Maillard reaction inhibitors containing them", XP002135575, retrieved from STN Database accession no. 129:104228 *
DATABASE WPI Section Ch Week 199748, Derwent World Patents Index; Class B03, AN 1997-516155, XP002148329 *
KHALIFAH R G (REPRINT) ET AL: "Effects of pyridoxamine, a novel post- Amadori AGE inhibitor, on nephropathy induced by glycated albumin.", JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, (SEP 1997) VOL. 8, SUPP. [S], PP. A2988-A2988. PUBLISHER: WILLIAMS & WILKINS, 351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436. ISSN: 1046-6673., UNIV KANSAS, MED CTR, SCH MED, KANSAS CITY, KS 66103;UNIV NIJMEGEN HOSP, DIV NEPHROL, NL-6500 HB NIJMEGEN, NETHERLANDS, XP000901589 *
KHALIFAH R G ET AL: "Amadorins: novel post- Amadori inhibitors of advanced glycation reactions.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, (1999 APR 13) 257 (2) 251-8. REF: 65, XP000891744 *
O. CHAPPEY ET AL.: "Advanced glycation end products, oxidant stress and vascular lesions", EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, vol. 27, 1997, pages 97 - 108, XP000949250 *
S FU ET AL.: "Presence of dopa and amino acid hydroperoxides in proteins modified with advanced glycation end products (AGEs): amino acid oxidation products as a possible source of oxidative stress induced by AGE proteins", BIOCHEMICAL JOURNAL, vol. 330, 1998, pages 233 - 239, XP000949249 *

Also Published As

Publication number Publication date
WO2000021516A2 (en) 2000-04-20
AU1112500A (en) 2000-05-01

Similar Documents

Publication Publication Date Title
DK1412357T3 (en) Beta-aminotetrahydroimidazo (1,2-a) pyrazines and tetrahydrotriazolo (4,3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
TW565451B (en) Compositions for the prevention of tolerance to medications
DE69827821D1 (en) Synergistic, analgetic composition with opiod-analgetika and zyklooxygenase-2 inhibitors
AP1445A (en) Substituted 4-amino-thiazol-2-yl compounds as cdksSubstituted 4-amino-thiazol-2-yl compounds as cdksinhibitors. inhibitors.
TW490458B (en) N-alkanoylphenylalanine derivatives, the preparation processes and uses thereof
AP1446A (en) Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors.
TW562674B (en) Compositions for treating or preventing inflammatory diseases
WO2004078138A3 (en) Prophylactic treatment of uv-induced epidermal neoplasia
TW530048B (en) New hydroxyindoles, their use as inhibitors of phosphodiesterase 4 and processes for their preparation
WO2007081740A3 (en) Micrornarna-based methods and compositions for the diagnosis and treatment of solid cancers
GB9604361D0 (en) 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
AU2001234979A1 (en) Methods and compositions for treating conditions of the eye
WO2002072031A3 (en) Substituted tetracycline compounds as synergistic antifungal agents
IL142121D0 (en) Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
PL218769B1 (en) Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
WO1995020960A3 (en) Dna damaging agents in combination with tyrosine kinase inhibitors
EP1247803A3 (en) Indolinone compounds suitable for modulation of protein kinases
WO2004009776A3 (en) TREATMENT OF TNFα RELATED DISORDERS
MXPA03000388A (en) Method for treating fibrotic diseases or other indications ic.
BR0213129A (en) Substituted polycyclic compound prodrugs useful for selective inhibition of coagulation cascade
TW200510334A (en) Preraration and use of aryl alkyl acid derivatives for the treatment of obesity
WO2007139955A8 (en) Triazole compounds that modulate hsp90 activity
WO2005005462A3 (en) Blys antagonists and uses thereof
ZA9703397B (en) Inhibitors of IMPDH enzyme.
AU6895801A (en) Heterocyclic compounds, which are inhibitors of the enzyme dpp-iv

Legal Events

Date Code Title Description
ENP Entry into the national phase in:

Ref country code: AU

Ref document number: 2000 11125

Kind code of ref document: A

Format of ref document f/p: F

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase